SGO Researchers Urge Special Treatment of Atypical Glandular Cells Found in Pap Smears

Publication
Article
OncologyONCOLOGY Vol 10 No 11
Volume 10
Issue 11

A typical glandular cells detected on cervical Pap smears indicate significant cervical pathology in 17% of cases and require an immediate work-up and biopsy, according to research reported in the October issue of Gynecologic Oncology, the scientific publication of the Society of Gynecologic Oncologists (SGO).

A typical glandular cells detected on cervical Pap smears indicatesignificant cervical pathology in 17% of cases and require animmediate work-up and biopsy, according to research reported inthe October issue of Gynecologic Oncology, the scientificpublication of the Society of Gynecologic Oncologists (SGO).

Although atypical glandular cells of undetermined significance(AGCUS) were found in only 0.2% of the more than 68,000 Pap smearsanalyzed in this 5-year study, compared with 4.5% of smears thathad the more common atypical squamous cells of undetermined significance(ASCUS), AGCUS results were much more ominous. Atypical glandularcells of undetermined significance often indicate infection orreparative changes and frequently only require repeat Pap smears.However, in this study, which reviewed a series of 77 patientswith AGCUS found on cytologic screening examinations, researchersdiscovered underlying cancer and/or significant precancerous lesionsin 17% of evaluated patients.

"Gynecologists aren't seeing a great deal of AGCUS in theiroffices because of its relative rarity. Therefore, women withAGCUS are often lumped into the same triage as ASCUS," saidstudy leader, Alexander W. Kennedy, md, Cleveland Clinic Foundation,Cleveland, Ohio. "But nearly 20% of these AGCUS smears willturn out to have significant abnormalities and need to be treatedimmediately and very differently than women with ASCUS results."

Based on their experience, these researchers have establishedinstitutional guidelines indicating that patients with AGCUS oncytologic screening should undergo immediate, intensive diagnosticstudies, including colposcopy, endocervical curettage, and endometrialbiopsy.

"Cervical adenocarcinomas are increasing in frequency, especiallyin young women. Physicians can't miss this opportunity to detectthese lesions early or at a precancerous stage," said SGOPresident David M. Genhenson, MD.

Recent Videos
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Related Content